Hims (HIMS) is a buy due to a new partnership with Novo Nordisk that resolves legal issues and opens up distribution of branded drugs, despite long-term competition concerns.
Source Post
If You Own HIMS Stock - Get Ready! 🚀
Ale's World of StocksMar 15, 2026
Hims (HIMS) stock is experiencing a significant rally following a new partnership with Novo Nordisk, which resolves a patent infringement lawsuit and allows Hims to distribute Novo's official weight loss drugs. While Hims will stop mass-marketing compounded versions, they will still offer them for specific clinical needs. The partnership is seen as a major win, reducing legal risk and tapping into branded demand, though long-term competition from giants like Amazon remains a concern for the creator.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.